AI bio startup Boltz raised a $110 million Series A, according to an announcement tied to the company’s recent public disclosures. The round follows less than a year after the company launched from stealth with $28 million and is positioned as additional runway to scale its AI-driven drug discovery capabilities. The disclosure signals continued capital flow into AI-first biotech models, with investors seeking faster iteration cycles and improved target-to-lead productivity. Boltz’s funding also suggests the market remains receptive to platform investments—especially those backed by early execution. For industry stakeholders, the main watch item is whether the company translates platform funding into staged advances such as lead optimization and preclinical selection milestones.
Get the Daily Brief